"uuid:ID","instanceType","description","id","label","rationale","name"
"6a842c2e-1cb9-4448-b65d-dee4d77f8ecf","StudyDesign","The main design for the study","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1"
